COMP <GO>
BTSG vs MRK // RSI-14 & 200D SMA MOMENTUM
BrightSpring Health Services Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: BTSG 3
— MRK 11
▲ RSI-14 & 200D SMA MOMENTUM LEADER: BTSG
LAST: $66.89 (+11.08%) • MKT CAP: $11.92B
rsi-technicals
67.3
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
rsi-technicals
56.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BTSG VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BTSG | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 11.80% | 74.80% | -63.00 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.50% | 20.70% | -15.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 37.9x | 15.3x | +22.60 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 3.31% | 3.42% | -0.11 | MRK | /fcf-yield <GO> |
| Operating Margin | 2.30% | 34.30% | -32.00 | MRK | /operating-margins <GO> |
| Net Profit Margin | 1.50% | 28.10% | -26.60 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 28.20% | 1.30% | +26.90 | BTSG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.92 | 5.19 | -1.27 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 67.3 | 56.9 | +10.40 | BTSG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.94 | 0.92 | +0.02 | BTSG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 52.9x | 18.4x | +34.50 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.92B | $361.02B | -$349.11B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BTSG REV | MRK REV | BTSG GROSS % | MRK GROSS % | BTSG FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.91B | $65.01B | 11.8% | 74.8% | $394.7M | $12.36B |
| FY 2024 | $10.07B | $64.17B | 12.6% | 76.3% | -$57.1M | $18.10B |
| FY 2023 | $7.69B | $60.12B | 44.0% | 44.0% | -$135.3M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BTSG // BETA 0.94
MRK // BETA 0.92